Endometriosis Treatment in India
Get Endometriosis Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Endometriosis Treatment in UAE
Endometriosis Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Endometriosis is a complex, often debilitating gynecological condition requiring expert surgical and hormonal management; with modern laparoscopic and robotic excision techniques, symptomatic remission is achieved in 70–90% of patients when treated by high-volume specialists. GAF Healthcare connects international patients with JCI- and NABH-accredited centers in India and JCI- and DHA-licensed hospitals in Dubai and Abu Dhabi, offering world-class endometriosis care at dramatically lower costs than Western countries. Whether you require conservative laparoscopic excision, deep infiltrating endometriosis (DIE) surgery, or a multidisciplinary fertility-preserving approach, GAF Healthcare coordinates every step of your medical journey.
Hospital Stay: 1–3 days (laparoscopic); 3–5 days (complex DIE or bowel resection cases) • Total Stay in Country (Fit-to-Fly): 1–3 weeks (laparoscopic excision); 3–6 weeks (bowel/urological involvement or open surgery) • Success Rate: 75–90% symptomatic relief; 40–60% natural conception improvement in infertility cases post-surgery
What Is It?
Endometriosis is a chronic, estrogen-dependent inflammatory condition in which endometrial-like tissue implants and proliferates outside the uterine cavity — most commonly on the ovaries, fallopian tubes, peritoneum, uterosacral ligaments, rectovaginal septum, bladder, and, in severe cases, the bowel and ureters. These ectopic lesions undergo cyclic hormonal stimulation analogous to the eutopic endometrium, generating localized inflammation, fibrosis, adhesion formation, and progressive pelvic organ distortion. The disease is staged using the revised American Society for Reproductive Medicine (rASRM) classification (Stage I–IV) as well as the more clinically nuanced Enzian classification for deep infiltrating endometriosis (DIE), which better predicts surgical complexity and fertility outcomes.
The physiological burden of endometriosis extends well beyond pelvic pain. Patients experience dysmenorrhea, deep dyspareunia, dyschezia, dysuria, chronic pelvic pain, and subfertility — all of which significantly impair quality of life. Inflammatory mediators including prostaglandins, interleukins, and tumor necrosis factor-alpha (TNF-α) are chronically elevated, creating a pro-inflammatory pelvic microenvironment. Ovarian endometriomas (chocolate cysts) additionally compromise ovarian reserve, with studies demonstrating reduced antral follicle counts (AFC) and anti-Müllerian hormone (AMH) levels in affected ovaries. The average diagnostic delay globally remains 7–10 years, underscoring the importance of seeking specialized, high-volume care.
The contemporary standard of care integrates a multimodal approach: accurate laparoscopic diagnosis with histological confirmation, complete surgical excision (rather than mere ablation) of all visible lesions, individualized medical suppression therapy, and long-term fertility or symptom management planning. Evidence strongly supports excision over ablation — particularly for DIE — owing to superior pain relief, lower recurrence rates, and improved fertility outcomes. Multidisciplinary teams including gynecologic surgeons, colorectal surgeons, urologists, reproductive endocrinologists, and pain specialists are essential for Stage III–IV disease. Robotic-assisted platforms (da Vinci Surgical System) are increasingly employed at leading Indian and UAE centers for enhanced precision in complex DIE, rectovaginal, and urological cases.
Candidates
• Women aged 18–50 experiencing chronic pelvic pain, dysmenorrhea, dyspareunia, or subfertility unresponsive to first-line analgesics or oral contraceptives
• Patients with ultrasound- or MRI-confirmed ovarian endometriomas (≥3 cm), deep infiltrating endometriosis, or extensive pelvic adhesions
• Women with documented subfertility (≥12 months) where endometriosis is the suspected or confirmed contributing factor, considering fertility-preserving excision prior to IVF
• Patients with rASRM Stage III–IV disease, Enzian Class B or C DIE involving the bowel wall, ureter, or bladder requiring multidisciplinary surgical planning
• Individuals who have failed or are intolerant to hormonal therapies (combined oral contraceptives, progestin-only therapy, GnRH agonists such as leuprolide acetate, or GnRH antagonists such as elagolix/relugolix)
• Patients with suspected endometriosis-related bowel obstruction, ureteral obstruction with hydronephrosis, or renal compromise
Required Pre-Operative Diagnostics:
• Transvaginal Ultrasound (TVUS) by an endometriosis-specialist sonographer using specific sliding sign protocols for DIE mapping
• Pelvic MRI with bowel preparation (MRI enterography protocol) for comprehensive DIE mapping including rectovaginal, bladder, and ureteral involvement
• Anti-Müllerian Hormone (AMH) and Antral Follicle Count (AFC) for ovarian reserve assessment prior to endometrioma surgery
• CA-125 serum level (useful as a monitoring biomarker; not diagnostic in isolation)
• Renal ultrasound or CT urogram if ureteral involvement is suspected on MRI
• Colonoscopy or rectal endoscopic ultrasound (EUS) where full-thickness bowel DIE is suspected
• Complete blood count, coagulation profile, liver and renal function tests, and hormonal panel (FSH, LH, estradiol)
Contraindications and Special Considerations:
• Active pelvic infection or endometritis (must be resolved prior to elective surgery)
• Severe cardiopulmonary compromise precluding general anesthesia and Trendelenburg positioning required for laparoscopy
• Patients desiring immediate pregnancy post-surgery: timing of conception versus adjuvant medical therapy must be carefully individualized
• Postmenopausal women: new-onset symptoms require exclusion of malignant transformation (endometriosis-associated ovarian cancer — clear cell or endometrioid subtypes) via imaging and CA-125/HE4 before planning surgery
Procedure
MEDICAL (HORMONAL) MANAGEMENT:
Hormonal suppression targets the estrogen-dependent proliferation of ectopic lesions. First-line agents include combined oral contraceptives (COCs) used cyclically or continuously and progestin-only preparations (norethindrone acetate, dienogest — the latter showing superior lesion-specific efficacy). Second-line therapies include GnRH agonists (leuprolide acetate depot, goserelin, nafarelin) inducing a hypoestrogenic state with add-back therapy to mitigate bone loss. Newer-generation oral GnRH antagonists — elagolix (Orilissa) and relugolix/estradiol/norethindrone acetate (Myfembree) — offer dose-titratable estrogen suppression with faster onset and offset, without the initial flare effect of GnRH agonists. The levonorgestrel-releasing intrauterine system (LNG-IUS / Mirena) is an effective long-term option for adenomyosis-associated or superficial peritoneal disease. Aromatase inhibitors (letrozole, anastrozole) in combination with progestins or COCs are reserved for refractory or postmenopausal disease.
SURGICAL MANAGEMENT — STANDARD LAPAROSCOPIC APPROACH:
Diagnostic and operative laparoscopy is the gold standard for definitive diagnosis and initial surgical treatment. Superficial peritoneal implants can be managed by electrosurgical ablation (monopolar or bipolar), laser vaporization (CO2 laser), or cold excision. However, excision is strongly preferred over ablation as it provides histological confirmation, removes the full depth of the lesion, and reduces recurrence rates. Ovarian endometriomas are treated via laparoscopic cystectomy (stripping technique) with meticulous attention to preserving surrounding healthy ovarian cortex to protect ovarian reserve. Adhesiolysis restores normal pelvic anatomy and improves fertility outcomes.
SURGICAL MANAGEMENT — DEEP INFILTRATING ENDOMETRIOSIS (DIE) SURGERY:
DIE surgery represents the highest complexity tier and requires a dedicated multidisciplinary team. Specific procedures include:
• Uterosacral ligament excision and presacral neurectomy (for central dysmenorrhea)
• Rectovaginal nodule excision with or without full-thickness rectal disc excision or segmental bowel resection and anastomosis (shaving, disc excision, or segmental resection based on nodule depth and circumferential involvement per Chapron/Koninckx classification)
• Bladder DIE excision with partial cystectomy and ureteral reimplantation (ureteroneocystostomy) when ureteral involvement is present
• Ureterolysis for extrinsic ureteral compression
• Diaphragmatic and thoracic endometriosis excision for catamenial pneumothorax (rare, specialist centers)
ROBOTIC-ASSISTED SURGERY (da Vinci Xi System):
Robotic platforms offer 3D high-definition visualization, instrument articulation with 7 degrees of freedom, tremor filtration, and ergonomic advantages during prolonged complex DIE cases. This translates to superior precision during rectovaginal dissection, ureteral identification, and microsurgical suturing (e.g., bowel anastomosis, cystotomy closure). Leading centers in India (Fortis, Apollo, Manipal) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai) maintain active robotic endometriosis programs.
FERTILITY-PRESERVING STRATEGIES:
For patients with endometriosis-related infertility, surgery aims to restore normal pelvic anatomy while maximally preserving ovarian reserve. Post-operative fertility planning includes timed conception, ovulation induction, intrauterine insemination (IUI), or IVF depending on remaining ovarian reserve (AMH), partner sperm parameters, and tubal status. In poor ovarian reserve cases, oocyte cryopreservation before endometrioma surgery should be considered and counseled.
EMERGING AND ADJUNCT THERAPIES:
Naltrexone (low-dose), pentoxifylline, and anti-TNF biologics are under investigation. Dienogest 2mg/day has the strongest evidence among progestins for post-operative medical suppression to delay recurrence. Endometriosis-specific pain rehabilitation programs integrating pelvic floor physiotherapy and psychological support are integral to comprehensive care.
Cost of Endometriosis Treatment: India vs. UAE
The cost of endometriosis treatment varies significantly based on disease stage, surgical complexity (simple laparoscopic excision versus multidisciplinary DIE with bowel or urological involvement), use of robotic technology, and hospital tier. Both India and the UAE offer internationally accredited centers with high-volume endometriosis surgeons, but India offers substantially lower pricing — typically 50–65% less than equivalent UAE costs — making it the preferred destination for cost-sensitive international patients. The UAE appeals to patients prioritizing proximity, luxury-tier hospital environments, and shorter travel distances from the Middle East, Europe, and Africa.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $2,500 – $9,000 | ~56% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $6,000 – $20,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL (4–8 WEEKS BEFORE TRAVEL):
• Submit medical records, operative reports, imaging (MRI/TVUS), hormonal profiles, and CA-125 to GAF Healthcare's coordination team
• GAF's partner gynecologic surgeons conduct a digital case review and provide a personalized surgical plan (laparoscopic excision, robotic DIE, or multidisciplinary bowel/urological case)
• Receive a detailed cost estimate, hospital admission timeline, and pre-operative optimization protocol
• Apply for Indian e-Medical Visa (processed within 72 hours via GAF's support) or confirm UAE tourist/medical visa status
• Pre-operative instructions: bowel preparation protocol (for DIE/bowel cases), cessation of NSAIDs and anticoagulants 5–7 days prior, hormonal therapy adjustment as directed by surgeon
PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (DAY 1–2):
• Airport pickup by GAF's dedicated medical concierge team; transfer to hospital or partner accommodation
• Comprehensive in-hospital workup: repeat TVUS or MRI review, anesthesia assessment, cardiopulmonary clearance, repeat blood panel, bowel prep (where applicable)
• Pre-operative consultation with the full surgical team including colorectal/urological co-surgeons for complex cases
• Surgical consent, anesthesia consent, and VTE (venous thromboembolism) prophylaxis planning
PHASE 3 — SURGICAL PROCEDURE (DAY 2–3):
• Surgery performed under general anesthesia; duration 1–2 hours (laparoscopic excision) to 4–6 hours (complex multidisciplinary DIE with bowel resection)
• Laparoscopic/robotic approach: 3–4 port entry; CO2 pneumoperitoneum; Trendelenburg positioning; systematic pelvic survey; sequential excision of all visible lesions
• For DIE with bowel involvement: colorectal surgeon performs shaving, disc excision, or segmental resection with stapled anastomosis; integrity tested intraoperatively
• Bladder/ureteral cases: urologist performs cystotomy repair or ureteroneocystostomy with double-J stent placement
• Intra-operative frozen section histology for suspicious lesions to exclude malignancy
PHASE 4 — IMMEDIATE POST-OPERATIVE RECOVERY (DAYS 3–5 IN HOSPITAL):
• Monitored recovery in surgical ward; IV analgesia (ketorolac, paracetamol, low-opioid multimodal protocol), early ambulation within 12–24 hours
• Urinary catheter removal Day 1–2 post-op (Day 5–7 for bladder repair cases)
• Bowel function assessment; liquid diet advancing to soft diet; nasogastric tube rarely required with ERAS (Enhanced Recovery After Surgery) protocols
• Drain removal when output <50 mL/24 hours; double-J ureteral stent removed at 4–6 weeks post-operatively (outpatient cystoscopy)
• Histopathology report reviewed with patient; post-operative hormonal plan (dienogest, GnRH antagonist, or LNG-IUS) initiated or planned
PHASE 5 — EARLY RECOVERY IN COUNTRY (DAYS 5–21):
• Discharge to GAF partner accommodation with 24/7 nursing helpline access
• Outpatient follow-up at Day 7 and Day 14: wound check, suture/port-site assessment, symptom review
• Pelvic rest (no intercourse, tampons, or heavy lifting >5 kg) for minimum 4 weeks
• Gradual return to walking; light activity from Week 2 onward
• Fit-to-fly clearance issued by operating surgeon (standard laparoscopic cases: 1–2 weeks; complex bowel/urological cases: 3–6 weeks)
PHASE 6 — LONG-TERM FOLLOW-UP (MONTHS 1–12):
• Telehealth follow-up with GAF's partner surgeon at 4–6 weeks, 3 months, and 6 months post-operatively
• MRI pelvis at 3–6 months to assess residual/recurrent disease
• AMH/AFC reassessment at 3 months if fertility is a concern
• Gynecologist in home country coordinates ongoing hormonal suppression therapy; GAF facilitates medical summary and imaging transfer
Risks & Considerations
Endometriosis surgery, while generally safe at high-volume centers, carries procedure-specific risks that patients must understand. Laparoscopic excision risks include port-site bleeding or hernia, inadvertent bowel or bladder entry, ureteral injury (incidence <1% at specialist centers but higher in DIE cases), and CO2 gas-related shoulder pain (typically resolves within 48 hours). Complex DIE surgery involving bowel resection carries risks of anastomotic leak (1–3%), bowel obstruction, fistula formation, and temporary or permanent colostomy in rare cases of extensive rectal involvement. Ureteral surgery risks include ureteral stricture, fistula, and renal impairment necessitating long-term stenting. Ovarian cystectomy for endometriomas carries a 2.4% risk of premature ovarian insufficiency per surgery, and repeat surgery substantially amplifies this risk — making AMH assessment and counseling mandatory. General anesthetic risks include VTE (mitigated by prophylactic LMWH and compression stockings), pulmonary complications, and anesthetic hypersensitivity. Recurrence remains a biological challenge: symptomatic recurrence rates are approximately 20–30% at 5 years even after complete surgical excision, necessitating post-operative medical suppression. Patients with Stage III–IV disease, DIE, or bilateral endometriomas have higher recurrence risk and require sustained surveillance. For fertility-seeking patients, post-operative pregnancy rates vary widely (20–60%) depending on patient age, ovarian reserve, partner factors, and disease severity — IVF should be discussed proactively when ovarian reserve is compromised.
Top Hospitals for Endometriosis Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Endometriosis Treatment
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Tarang Preet Kaur
MBBS, MS, MRCOG, MCh, Fellowship in Urogynaecology, Fellowship in Cosmetic Gynaecology
Urogynaecologist
Max Super Speciality Hospital, Saket, New Delhi, India
11+ Yearsof experience
Dr. Tarang Preet Kaur is a Consultant in Urogynaecology with over 11 years of clinical experience, currently practicing at Max Super Speciality Hospital, Saket in New Delhi. She holds an MCh in Urogynaecology from Edge Hill University, United Kingdom (2024), the MRCOG from the Royal College of Obstetricians & Gynaecologists, and an MS in Obstetrics & Gynaecology from Maulana Azad Medical College, Delhi. Her dual qualification across India and the UK… Read more
Dr. Amrinder Kaur Bajaj
MBBS, MD — Obstetrics & Gynaecology (Gold Medalist), Senior Residency — Obstetrics & Gynaecology, FRSH — Fellow of the Royal Society of Health, FIAMS — Fellow of the Indian Association of Medical Specialists
Obstetrician & Gynaecologist
Fortis Hospital, Gurgaon, Gurgaon, India
42+ Yearsof experience
Dr. Amrinder Kaur Bajaj is one of Delhi-NCR's most experienced gynaecologists, with over four decades spent caring for women at every stage of life. She currently practises as a Consultant in Obstetrics & Gynaecology at Fortis Hospital, Gurgaon, where she brings together deep clinical knowledge and a quietly reassuring bedside manner that patients — and their families — find genuinely comforting. Her academic journey set a high bar early on. She completed… Read more
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Dr. Aswari Kesari Kapoor
MBBS, DGO (Diploma in Gynaecology & Obstetrics), CPS (College of Physicians and Surgeons), DNB (Diplomate of National Board) — Obstetrics & Gynaecology
Obstetrician & Gynecologist
Indraprastha Apollo Hospital, New Delhi, India
23+ Yearsof experience
Dr. Aswari Kesari Kapoor is a seasoned Obstetrician and Gynecologist with over 23 years of hands-on clinical experience. She practices at Indraprastha Apollo Hospital in New Delhi — one of India's most respected multi-specialty institutions. Over the course of her career, she has built a strong reputation for managing complex gynecological conditions alongside high-risk pregnancies, all with a calm and reassuring bedside manner that patients consistently… Read more
Dr. Bindhu K S
MBBS, DNB (Obstetrics & Gynecology), Fellowship in Minimal Access Surgery, FICOG (Fellowship of the Indian College of Obstetricians and Gynaecologists), Certificate in Gynecologic and Obstetric Sonography, Certificate in Appreciation of Well Being in Fetal Heart Disease
Obstetrician & Gynecologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
23+ Yearsof experience
Dr. Bindhu K S is a seasoned Obstetrician and Gynecologist based in Mumbai, currently practicing at Apollo Hospitals, Navi Mumbai. With over two decades of clinical experience, she brings together expertise in both obstetrics and advanced minimally invasive gynecologic surgery. Whether a patient comes with a complex fibroid, troublesome endometriosis, or a high-risk pregnancy, Dr. Bindhu approaches each situation with careful thought and genuine care. Her… Read more
Frequently Asked Questions — Endometriosis Treatment
The cost of endometriosis treatment depends heavily on disease complexity and surgical approach. In India, laparoscopic excision for Stage I–II endometriosis at a JCI- or NABH-accredited hospital typically costs between $2,500 and $5,500 USD, while complex multidisciplinary deep infiltrating endometriosis (DIE) surgery involving bowel resection, ureteral surgery, or robotic-assisted platforms ranges from $5,500 to $9,000 USD. In the UAE (Dubai or Abu Dhabi), equivalent procedures cost approximately $6,000 to $10,000 USD for standard laparoscopic cases and $12,000 to $20,000 USD for complex DIE at JCI- and DHA-accredited centers. Both destinations offer substantial savings compared to the United States ($15,000–$50,000+) or United Kingdom ($10,000–$30,000+). India offers the most significant cost advantage — typically 55–65% lower than the UAE — while the UAE appeals to patients from the Middle East, Africa, and Europe who prioritize proximity, luxury hospital environments, and shorter travel distances. GAF Healthcare provides transparent, all-inclusive cost estimates encompassing surgeon fees, hospital stay, anesthesia, operating theater, medications, and post-operative follow-up consultations.
Fit-to-fly clearance following endometriosis surgery depends on the type and complexity of the procedure performed. For standard laparoscopic excision of superficial peritoneal disease, ovarian endometriomas (cystectomy), or limited adhesiolysis, most patients are discharged within 1–3 days and can safely fly home within 7–14 days of surgery, once wound healing is confirmed and pain is adequately controlled with oral analgesia. For complex deep infiltrating endometriosis (DIE) surgery involving bowel shaving, disc excision, or segmental bowel resection and anastomosis, ureterolysis, or partial cystectomy, a longer in-country stay of 3–6 weeks is strongly recommended. This allows time for assessment of anastomotic integrity, drain removal, ureteral stent management, and confidence in bowel function before undertaking a long-haul flight. Long-haul flights (exceeding 4–6 hours) carry an elevated deep vein thrombosis (DVT) and pulmonary embolism (PE) risk in the early post-operative period; all patients receive individualized VTE risk assessment and prophylaxis guidance from their surgical team before clearance is granted. GAF Healthcare's operating surgeons provide a written fit-to-fly certificate once all milestones are met, and telehealth follow-up is arranged for the first weeks after the patient returns home.
The success of endometriosis treatment is measured across several clinical endpoints: pain relief, symptom recurrence, and fertility outcomes. For surgical excision of endometriosis, 75–90% of patients report clinically significant improvement in pelvic pain, dysmenorrhea, and dyspareunia following complete laparoscopic or robotic excision of all visible disease — with outcomes consistently superior to ablation alone or medical therapy alone. Symptom recurrence rates are approximately 20–30% at 5 years for surgical patients; this risk is significantly reduced by post-operative medical suppression therapy (dienogest, GnRH antagonists, or LNG-IUS). For women with endometriosis-related infertility, surgical excision of Stage I–II disease improves natural conception rates by approximately 40–60% compared to expectant management. In Stage III–IV disease with significant ovarian or tubal involvement, natural conception rates post-surgery range from 20–40%, with IVF success rates of 30–50% per cycle in centers with dedicated reproductive endocrinology programs. Robotic-assisted DIE surgery at high-volume specialist centers is associated with lower intra-operative complication rates, lower conversion-to-open rates (<1%), shorter hospital stays, and equivalent or superior long-term symptom relief compared to standard laparoscopy in complex cases. The single greatest determinant of success is complete excision of all lesions at the index surgery by a surgeon with dedicated endometriosis expertise — which is precisely the standard GAF Healthcare partners consistently deliver.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end coordination for international patients traveling to India or the UAE for endometriosis treatment, ensuring that non-medical logistics are fully managed so patients can focus entirely on their recovery.
INDIA — VISA & ENTRY: GAF Healthcare assists patients in applying for the Indian e-Medical Visa online, which is typically approved within 48–72 hours and permits a stay of up to 60 days, extendable if recovery requires. One attendant (spouse, parent, or companion) is eligible for an e-Medical Attendant Visa simultaneously. GAF provides an official hospital invitation letter required as part of the visa application. Citizens of most countries (180+) are eligible for the e-Medical Visa.
UAE — VISA & ENTRY: The UAE offers visa-free entry to passport holders from over 60 countries (GCC nationals, most EU/UK citizens, US, Canada, Australia, and others). Patients requiring a visa can obtain a 30- or 90-day UAE tourist visa on arrival or through an online portal. GAF's UAE concierge team can facilitate medical visa letters from DHA-licensed hospitals if required for extended stays. No specific 'medical visa' category exists in the UAE; standard tourist visas suffice for medical travel.
AIRPORT TRANSFERS & GROUND LOGISTICS: Dedicated, air-conditioned vehicle transfers are arranged from the airport to the hospital and subsequently to partner accommodations. Post-discharge, all follow-up appointment transfers are included. Wheelchair assistance and porter services are coordinated for patients with severe pain or limited mobility.
DEDICATED MEDICAL INTERPRETERS: GAF provides professional medical interpreters for Arabic, Russian, French, Swahili, and other major languages at no additional cost, available during surgeon consultations, consent discussions, and discharge briefings. Interpreters are medically trained to ensure clinical accuracy rather than general translation.
ATTENDANT ACCOMMODATION: GAF partners with curated serviced apartments, guesthouses, and hospital-adjacent hotels across Delhi, Mumbai, Chennai, Hyderabad, Dubai, and Abu Dhabi. Accommodation packages for one or two attendants are included in standard GAF coordination packages, with options ranging from budget-friendly to luxury depending on preference. Meal planning, pharmacy access, and SIM card provisioning for local communication are all coordinated by the GAF concierge team.
TELEMEDICINE & CONTINUITY OF CARE: Post-discharge, GAF's platform facilitates encrypted video consultations between the patient and the treating surgeon for all follow-up appointments. A comprehensive medical summary, operative report, histopathology results, and post-operative imaging are compiled and transferred in formats compatible with international healthcare systems, enabling seamless handover to the patient's home-country gynecologist.